Table 3.
Published molecular testing rates for patients with metastatic NSCLC across participating European countries.
| Austria70 | Belgiuma | Czech Republicc | England71 | France72 | Germany73 | Netherlands44,74 | Portugal | Slovenia61 | Spain75 | Swedend | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EGFR | 77.1% | 51% | 79.3% | 92% | 53% | 72.5% | ∼60–82%b | No data | 91% | 91.4% | No data (authors estimate: ∼90%) |
| Year(s) of data | (2013–2015) | (2011) | (2011) | (2017) | (2015–2018) | (2015–2019) | (2017) | (Single center, 2020) | (2018–2019) | ||
| ALK | 62.5% | No data | 82.7% | 80% | 46% | 74.5% | ∼35%–55%b,e | No data | 87% | 80.1% | No data (authors estimate: ∼90%) |
| Year(s) of data | (2013–2015) | (2013) | (2017) | (2015–2018) | (2015–2019) | (2017) | (Single center, 2018) | (2018–2019) | |||
| ROS1 | No data | No data | 82.7% | No data | 34% | 66.1% | ∼28–38%b,f | No data | 86% | 56.2% | No data (authors estimate: ∼90%) |
| Year(s) of data | (2015) | (Mutation and/or fusion, 2015–2018) | (2015–2019) | (2017, total) | (Single center, 2018) | (2018–2019) | |||||
| BRAF | No data | No data | No data | No data | 38% | 53.0% | ∼60–78%b | No data | No data | No data | No data (authors estimate: ∼70%) |
| Year(s) of data | (2015–2018) | (2015–2019) | (2017) | ||||||||
| RET | No data | No data | No data | No data | No data | 26.9% | ∼18–19%b,g | No data | No data | No data | No data (authors estimate: ∼70%) |
| Year(s) of data | (2015–2019) | (2017, in total) | |||||||||
| MET mut. | No data | No data | No data | No data | 12% | 35.4% | ∼55–68%b | No data | No data | No data | No data (authors estimate: ∼70%) |
| Year(s) of data | (Mutation and/or fusion, 2015–2018) | (2015–2019) | (2017) | ||||||||
| MET amp. | No data | No data | No data | No data | See ‘MET mut.’ | No data | No data | No data | No data | No data | No data |
| Year(s) of data | |||||||||||
| KRAS | No data | No data | No data | No data | 45% | 44.9% | 82.0% | No data | No data | No data | No data (authors estimate: ∼70%) |
| Year(s) of data | (2015–2018) | (2015–2019) | (2017) | ||||||||
| NTRK | No data | No data | No data | No data | No data | No data | No data | No data | No data | No data | No data (authors estimate: ∼50%) |
| Year(s) of data | |||||||||||
| HER2/ERBB2 | No data | No data | No data | No data | 30% | 15.2% | ∼55–76%b | No data | No data | No data | No data (authors estimate: ∼50%) |
| Year(s) of data | (2015–2018) | (2015–2019) | (2017) | ||||||||
| NRG1 | No data | No data | No data | No data | No data | No data | No data | No data | No data | No data | No data (authors estimate: ∼20%) |
| Year(s) of data | |||||||||||
| PD-L1 | No data | No data | 89.5% | 87% | 17% | 66.2% | No data | No data | 74–91% | 58.1% | No data (authors estimate: ∼90%) |
| Year(s) of data | (2016) | (2017) | (2015–2018) | (2015–2019) | (Single center, 2018) | (2019–2020) |
Recent data not publicly available, but could be requested at RIZIV and Belgian Cancer registration.
Higher rate is applicable to adenocarcinoma, lower rate is applicable to NSCLC-NOS.
National testing rates from national cancer registry, calculated from cases eligible for molecular testing (e.g., molecular testing for NSCLC NOS and adenocarcinoma, PD-L1 for all NSCLC).
No public data available on testing rates, displayed numbers are the Swedish authors’ estimations based on their expected national adherence to guidelines, personal communication of authors, degree of sequential testing.
∼70–80% if EGFR/KRAS/BRAF/ERBB2/MET wildtype.
∼60–70% if EGFR/KRAS/BRAF/ERBB2/MET wildtype.
∼42–44% if EGFR/KRAS/BRAF/ERBB2/MET wildtype.